Equity Profile

CRNX

Crinetics Pharmaceuticals, Inc.

Health CarePharmaceuticals$3.7B

May7Thu

Post-Earnings Recap

ReportedQ1-2026After Close4:05 PM EDT

Crinetics Pharmaceuticals Misses on Revenue, Stock Up 4.27%

Metric	Actual	Expected	Surprise
EPS	$-1.23	$-1.24	+0.82%
Revenue	—	$9M	—

management commentary, guidance changes, and full analysis available with Pro.

Crinetics Pharmaceuticals Misses on Revenue, Stock Up 4.27%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$-1.23	$-1.24	+0.82%
Revenue	—	$9M	—

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Crinetics Pharmaceuticals reported a narrower loss per share than expected, which may have contributed to the positive stock reaction. However, the lack of revenue and guidance leaves uncertainty about future performance. Investors may be cautiously optimistic due to the slight EPS beat, but the absence of revenue figures raises questions.

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases and metabolic disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-1.24

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$9M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases and metabolic disorders. With a market cap of $4 billion, its work in pharmaceuticals is crucial as it addresses unmet medical needs in these specialized areas.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

+1.78%

Last Quarter Recap

In Q4 2025, Crinetics reported an EPS of $-1.29, slightly better than the expected $-1.37, indicating a small positive surprise. However, revenue details were not disclosed, leaving some uncertainty about sales performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Crinetics to report a loss of $-1.24 per share on revenues of $9 million for Q1 2026. The market is closely watching these figures to gauge the company's progress in its drug development pipeline.

Bull Case

If Crinetics can exceed revenue expectations and show signs of progress in its clinical trials, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company reports a wider loss than expected or fails to provide clarity on its drug development progress, it could lead to a negative reaction from investors.

Key Metrics to Watch

EPS

$-1.24

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$9M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue for Q1 2026 and how does it compare to the consensus of $9 million?

Revenue performance will be a key indicator of market demand for Crinetics' products and its overall financial health.

What updates can management provide on the progress of its drug development pipeline?

Investors will be looking for clarity on the company's future prospects and any potential catalysts that could drive growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating the potential for Crinetics to exceed revenue expectations due to recent positive trends in its drug pipeline.

Supporting Evidence

The company has a history of surprising analysts with better-than-expected EPS, as seen in the last quarter.

The options market is pricing in a significant move, suggesting that traders anticipate volatility and potential positive news.

Key Risk

If revenue comes in significantly above $9 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will hinge on revenue performance and updates on drug development, which are critical for investor confidence.

Bull Confirmed If

Reporting revenue above $9 million and demonstrating progress in clinical trials would confirm the bull case.

Bear Confirmed If

A wider loss than the expected $-1.24 EPS would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.7%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move of about 10.7%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±21.6% while CRNX has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

30d HV

44.2%

Calls (700)P/C Ratio: 13.80Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 3.9%, with a raw directional average of +1.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Crinetics beats expectations, history suggests the stock could rise by about 1.42%, confirming a positive outlook.

In-Line / Cautious

A cautious in-line report may lead to a muted response, reflecting uncertainty in the market.

Miss

If the company misses expectations, history suggests a potential decline of around 0.71%, indicating investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of clinical trials for key drugs in the pipeline.
2Details on revenue sources and whether they align with the consensus estimate.
3Management's outlook on future product launches and market strategies.
4Insights into any regulatory developments that could impact the business.
5Responses to investor questions regarding cost management and operational efficiency.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

BMRNReported

BioMarin Pharmaceutical Inc.

RecapView

May4

PLTRReported

Company Snapshot

Crinetics Pharmaceuticals, Inc. is a healthcare company focused on developing innovative therapies for endocrine diseases and metabolic disorders....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$-1.24

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$9M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-3.44%

Avg Stock Reaction

+1.78%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Crinetics can exceed revenue expectations and show signs of progress in its clinical trials, it could lead to a positive market reaction and increased investor confidence.

Bear Case

Conversely, if the company reports a wider loss than expected or fails to provide clarity on its drug development progress, it could lead to a negative reaction from investors.

Key Metrics to Watch

EPS

$-1.24

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$9M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue for Q1 2026 and how does it compare to the consensus of $9 million?

Revenue performance will be a key indicator of market demand for Crinetics' products and its overall financial health.

What updates can management provide on the progress of its drug development pipeline?

Investors will be looking for clarity on the company's future prospects and any potential catalysts that could drive growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may be underestimating the potential for Crinetics to exceed revenue expectations due to recent positive trends in its drug pipeline.

Supporting Evidence

The company has a history of surprising analysts with better-than-expected EPS, as seen in the last quarter.

The options market is pricing in a significant move, suggesting that traders anticipate volatility and potential positive news.

Key Risk

If revenue comes in significantly above $9 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will hinge on revenue performance and updates on drug development, which are critical for investor confidence.

Bull Confirmed If

Reporting revenue above $9 million and demonstrating progress in clinical trials would confirm the bull case.

Bear Confirmed If

A wider loss than the expected $-1.24 EPS would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±10.7%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move of about 10.7%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±21.6% while CRNX has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

30d HV

44.2%

Calls (700)P/C Ratio: 13.80Puts (200)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 3.9%, with a raw directional average of +1.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Crinetics beats expectations, history suggests the stock could rise by about 1.42%, confirming a positive outlook.

In-Line / Cautious

A cautious in-line report may lead to a muted response, reflecting uncertainty in the market.

Miss

If the company misses expectations, history suggests a potential decline of around 0.71%, indicating investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of clinical trials for key drugs in the pipeline.
2Details on revenue sources and whether they align with the consensus estimate.
3Management's outlook on future product launches and market strategies.
4Insights into any regulatory developments that could impact the business.
5Responses to investor questions regarding cost management and operational efficiency.